Hottest Stocks (Over $10)	Hottest Stocks ($2-$10)	Biggest Losers (Over $10)	Biggest Losers ($2-$10)	Hottest Industries	Hottest Sectors	EPS / Sales Surprises
Enter Ticker Symbol:   Ticker Lookup Company Quote Company Profile Research Summary EPS Consensus Perspective Insider Transactions Price Performance

Enter any portion of the company’s name to find its corresponding ticker symbol:

Search for :

Zacks Company Profile for Adaptive Biotechnologies Corporation (ADPT : NSDQ)

• Company Description    Adaptive Biotechnologies Corporation is a commercial-stage biotech company. It develops and commercializes immune-driven clinical products to transform the diagnosis and treatment of disease. The company's product pipeline includes immunoSEQ, clonoSEQ and cellular therapy which are in clinical stage. Adaptive Biotechnologies Corporation is based in Seattle, Washington. Number of Employees: 619

• Price / Volume Information    Yesterday's Closing Price: $16.24 Daily Weekly Monthly 20 Day Moving Average: 2,425,075 shares Shares Outstanding: 152.66 (millions) Market Capitalization: $2,479.28 (millions) Beta: 2.18 52 Week High: $20.76 52 Week Low: $5.98 Short Interest Ratio:   % Price Change % Price Change Relative to S&P 500 4 Week -6.99% -6.83% 12 Week 3.77% 2.10% Year To Date 0.00% 0.00%

• Address & Contact Information Street Address Phone / Fax Email Address Web URL 1165 EASTLAKE AVENUE EAST SUITE 200 - SEATTLE,WA 98109 USA ph: 206-659-0067 fax: 206-659-0667 investors@adaptivebiotech.com http://www.adaptivebiotech.com

• General Corporate Information    Officers Chad Robins - Chief Executive Officer and Director Kyle Piskel - Chief Financial Officer Michelle Griffin - Director Robert Hershberg - Director Peter Neupert - Director Peer Information Adaptive Biotechnologies Corporation (CORR.) Adaptive Biotechnologies Corporation (RSPI) Adaptive Biotechnologies Corporation (CGXP) Adaptive Biotechnologies Corporation (BGEN) Adaptive Biotechnologies Corporation (GTBP) Adaptive Biotechnologies Corporation (RGRX) Industry / Sector / Ticker Info Analyst Coverage: No Industry Group: MED-BIOMED/GENE Sector: Medical CUSIP: 00650F109 SIC: 2836 Fiscal Year Fiscal Year End: December Last Reported Quarter: 09/01/25 Next Expected EPS Date: 02/10/26 Share - Related Items Shares Outstanding: 152.66 Most Recent Split Date: (:1) Beta: 2.18 Market Capitalization: $2,479.28 (millions)

• EPS Information     • Dividend Information Analyst Coverage: No Dividend Yield: 0.00% Current Fiscal Quarter EPS Consensus Estimate: $-0.17 Indicated Annual Dividend: $0.00 Current Fiscal Year EPS Consensus Estimate: $-0.59 Payout Ratio: Number of Estimates in the Fiscal Year Consensus: 4.00 Change In Payout Ratio: Estmated Long-Term EPS Growth Rate: % Last Dividend Paid: NA - $0.00 Next EPS Report Date: 02/10/26

• Fundamental Ratios P/E Current FY Estimate: - Trailing 12 Months: - PEG Ratio: - Price Ratios Price/Book: 12.11 Price/Cash Flow: - Price / Sales: 9.81 EPS Growth vs. Year Ago Period: 31.82% vs. Previous Quarter: 11.76% Sales Growth vs. Year Ago Period: 102.38% vs. Previous Quarter: 59.60% ROE 12/31/25 - - 09/30/25 - -58.40 06/30/25 - -60.93 ROA 12/31/25 - - 09/30/25 - -22.25 06/30/25 - -23.03 Current Ratio 12/31/25 - - 09/30/25 - 3.38 06/30/25 - 2.84 Quick Ratio 12/31/25 - - 09/30/25 - 3.26 06/30/25 - 2.75 Operating Margin 12/31/25 - - 09/30/25 - -44.85 06/30/25 - -59.07 Net Margin 12/31/25 - - 09/30/25 - -31.50 06/30/25 - -59.07 Pre-Tax Margin 12/31/25 - - 09/30/25 - -31.49 06/30/25 - -59.08 Book Value 12/31/25 - - 09/30/25 - 1.34 06/30/25 - 1.18 Inventory Turnover 12/31/25 - - 09/30/25 - 8.03 06/30/25 - 7.44 Debt-to-Equity 12/31/25 - - 09/30/25 - 0.00 06/30/25 - 0.00 Debt-to-Capital 12/31/25 - - 09/30/25 - 0.00 06/30/25 - 0.00

Powered by Zacks Investment Research ©